[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 30 of about 30
1. Kasamatsu T, Onda T, Sawada M, Kato T, Ikeda S: Radical hysterectomy for FIGO stage IIB cervical cancer: clinicopathological characteristics and prognostic evaluation. Gynecol Oncol; 2009 Jul;114(1):69-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radical hysterectomy for FIGO stage IIB cervical cancer: clinicopathological characteristics and prognostic evaluation.
  • OBJECTIVE: To clarify the clinicopathological features and prognostic factors of patients with FIGO stage IIB cervical cancer who were treated with radical hysterectomy.
  • METHODS: One hundred thirty-nine FIGO stage IIB patients with squamous or adenosquamous cell carcinoma (median age, 51 years) who were treated with primary radical hysterectomy were examined retrospectively.
  • Sixty-six FIGO stage IIB patients who were treated with primary radiotherapy (median age, 70 years) were included for comparison of survival.
  • CONCLUSION: Pathological parametrial involvement and positive nodes were prognostic factors for surgically treated patients with FIGO stage IIB cervical cancer.
  • [MeSH-major] Hysterectomy / methods. Uterine Cervical Neoplasms / pathology. Uterine Cervical Neoplasms / surgery
  • [MeSH-minor] Aged. Carcinoma, Adenosquamous / pathology. Carcinoma, Adenosquamous / radiography. Carcinoma, Adenosquamous / surgery. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiography. Carcinoma, Squamous Cell / surgery. Disease-Free Survival. Female. Humans. Lymphatic Metastasis. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Prognosis. Proportional Hazards Models. Survival Rate. Survivors


2. Pasricha R, Tiwari A, Aggarwal T, Lal P: Carcinoma of uterine cervix with isolated metastasis to fibula and its unusual behavior: report of a case and review of literature. J Cancer Res Ther; 2006 Apr-Jun;2(2):79-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carcinoma of uterine cervix with isolated metastasis to fibula and its unusual behavior: report of a case and review of literature.
  • Bone metastasis from carcinoma cervix is uncommon, especially in the distal appendicular skeleton.
  • A 36 year old lady presented with carcinoma of uterine cervix, FIGO, stage IIb.
  • This is one of the few documented cases of metastasis to fibula, arising from carcinoma of uterine cervix and probably the first with isolated metastasis of this site.
  • [MeSH-major] Bone Neoplasms / secondary. Carcinoma, Squamous Cell / secondary. Fibula / pathology. Uterine Cervical Neoplasms / pathology


3. Devkota B, Patel H: Meningeal carcinomatosis from cervical cancer: a case report and review of the literature. Hosp Pract (1995); 2010;38(3):117-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Meningeal carcinomatosis from cervical cancer: a case report and review of the literature.
  • Meningeal carcinomatosis (MC) from cervical cancer is rare.
  • We report an interesting case of MC from the uterine cervix and review general diagnostic and treatment considerations.
  • The patient received chemotherapy and radiotherapy for stage IIB cervical cancer with resolution of symptoms for 3 years.
  • [MeSH-major] Meningeal Carcinomatosis / secondary. Neoplasms, Squamous Cell / secondary. Uterine Cervical Neoplasms / pathology


Advertisement
4. Tian ZZ, Li S, Liu ML, Zhu XH, Zhao R, Yue YJ, Chen XH: [Clinical value of the comprehensive treatment in intermediate and advanced cervical cancer with uterine arterial interventional chemoembolization and radiotherapy]. Zhonghua Fu Chan Ke Za Zhi; 2010 Jul;45(7):506-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical value of the comprehensive treatment in intermediate and advanced cervical cancer with uterine arterial interventional chemoembolization and radiotherapy].
  • OBJECTIVE: To investigate the long-term curative effect of the radiotherapy combined uterine arterial interventional chemoembolization for cervical cancer.
  • METHODS: Records of 632 patients with cervical cancer stage II - IVa proved by pathology in Lanzhou Command General Hospital from January 1st, 1999 to August 31st, 2009 were retrospective analysed.
  • One hundred and twenty-six cases of them were treated with radical radiotherapy combined uterine arterial interventional chemoembolization (arterial chemoembolization + radiotherapy group), 506 cases of them were treated with radical radiotherapy only (radiotherapy group); the evaluation of the late radiation injury was done, according to Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer (RTOG/EORTC) advanced radiation injury criteria.
  • During the follow-up period, the rate of recurrence and metastasis in arterial chemoembolization + radiotherapy group were 77.0% (97/126), while 73.3% (371/506) in radiotherapy group (χ(2) = 0.705, P = 0.401). (2) Radiotherapy complications and relative risk factors: the total incidence of tardive bladder injury higher than RTOG/EORTC stage II was 5.5% (35/632), while it was 11.1% (14/126) in arterial chemoembolization + radiotherapy group, 4.2% (21/506) in the radiotherapy group (χ(2) = 9.344, P = 0.002).
  • The results of logistic regression showed that the uterine arterial interventional chemoembolization was relative risk factors of the tardive bladder injury (χ(2) = 6.440, OR = 2.869, P = 0.011).
  • CONCLUSIONS: Compared with the simple radiotherapy, there are a similar short-term survival rate and significant poor 5-year, 8-year survival rate in the patients treated with the uterine arterial interventional chemoembolization combined with radiotherapy, which also may be strong dangerous factor for the occurrence of tardive bladder injury.
  • The results shown that the uterine arterial interventional chemoembolization do not recommend to be routine adjuvant therapy for the radical radiotherapy of cervical cancer.
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Carcinoma, Squamous Cell / therapy. Chemoembolization, Therapeutic. Cisplatin / administration & dosage. Fluorouracil / administration & dosage. Radiotherapy. Uterine Cervical Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Cyclophosphamide / therapeutic use. Female. Follow-Up Studies. Humans. Infusions, Intra-Arterial. Middle Aged. Neoplasm Staging. Prognosis. Radiography, Interventional. Retrospective Studies. Survival Rate. Treatment Outcome. Uterine Artery. Young Adult


5. Kümmel S, Thomas A, Jeschke S, Hauschild M, Sehouli J, Lichtenegger W, Blohmer JU: Postoperative therapy modalities for cervical carcinoma. Anticancer Res; 2006 Mar-Apr;26(2C):1707-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Postoperative therapy modalities for cervical carcinoma.
  • Currently, the standard therapy for cervical carcinoma of FIGO stage IIB following adequate radical surgery is simultaneous radiochemotherapy with a platinous chemotherapeutic agent.
  • According to the current state of scientific knowledge, all patients of FIGO stages IIA-IB with at least one additional risk factor (adenocarcinoma, pN1, L1, V1, pT1b2) also benefit from adjuvant radiochemotherapy.
  • The data regarding a possible survival advantage following an increase in the hemoglobin content in the blood of cancer patients by erythropoietin administration is still contradictory.
  • Several studies are currently being conducted into the effectiveness of such new therapies on both life expectancy and quality of life (e.g., Cervix-NOGGO-AGO-Uterus 7-study).
  • [MeSH-major] Uterine Cervical Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16617565.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Hemoglobins
  • [Number-of-references] 63
  •  go-up   go-down


6. Gupta T, Nair N, Fuke P, Bedre G, Basu S, Shrivastava SK: Splenic metastases from cervical carcinoma: a case report. Int J Gynecol Cancer; 2006 Mar-Apr;16(2):911-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Splenic metastases from cervical carcinoma: a case report.
  • Splenic metastasis from squamous cell carcinoma of the uterine cervix is an unusual event in the natural history of the disease.
  • The authors report one such uncommon occurrence in a 41-year-old female who presented initially with cervical carcinoma (stage IIB) and was treated with radical radiotherapy with concurrent weekly chemotherapy.
  • This report reaffirms the notion that splenic metastases from cervical carcinoma are rare events but can occur as part of widespread dissemination.
  • [MeSH-major] Carcinoma, Squamous Cell / secondary. Splenic Neoplasms / secondary. Uterine Cervical Neoplasms / pathology


7. Nasu K, Takai N, Narahara H: Multimodal treatment for glassy cell carcinoma of the uterine cervix. J Obstet Gynaecol Res; 2009 Jun;35(3):584-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multimodal treatment for glassy cell carcinoma of the uterine cervix.
  • Glassy cell carcinoma of the uterine cervix is a rare form of cervical cancer that is characterized by aggressiveness and poor prognosis because of its rapid growth, its frequent distant metastases, and its relative resistance to conventional treatment modalities including surgery, radiotherapy, and chemotherapy.
  • We report here a case of glassy cell carcinoma of the uterine cervix that was successfully treated with radical surgery followed by radiation therapy and combination chemotherapy with paclitaxel and carboplatin.
  • A 30-year-old primigravid Japanese woman was admitted to our hospital to be treated for stage IIb uterine cervical cancer.
  • The pathological diagnosis of the surgical specimen was glassy cell carcinoma of the uterine cervix with metastases to the right obturator lymph nodes and left external iliac lymph nodes.
  • It is suggested that multimodal therapy with radical surgery, radiation, and combined chemotherapy should be used to treat glassy cell carcinoma of the uterine cervix.
  • [MeSH-major] Carcinoma, Adenosquamous / therapy. Uterine Cervical Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19527406.001).
  • [ISSN] 1341-8076
  • [Journal-full-title] The journal of obstetrics and gynaecology research
  • [ISO-abbreviation] J. Obstet. Gynaecol. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


8. Lim MC, Kim JY, Kim TH, Park S, Kong SY, Yoon JH, Kang S, Seo SS, Park SY: Allogeneic blood transfusion given before radiotherapy is associated with the poor clinical outcome in patients with cervical cancer. Yonsei Med J; 2008 Dec 31;49(6):993-1003
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allogeneic blood transfusion given before radiotherapy is associated with the poor clinical outcome in patients with cervical cancer.
  • PURPOSE: To analyze the effect of allogeneic blood transfusion on clinical outcome in 119 patients with stage IIB cervical cancer who were treated with radiotherapy +/- chemotherapy.
  • CONCLUSION: Our results suggest that allogeneic blood transfusions given before radiotherapy may be associated with higher incidence of distant metastases and decreased survival in patients with stage IIB cervical cancer.
  • [MeSH-major] Blood Transfusion / adverse effects. Uterine Cervical Neoplasms / radiotherapy. Uterine Cervical Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anemia / etiology. Anemia / therapy. Carcinoma, Squamous Cell / complications. Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / secondary. Carcinoma, Squamous Cell / therapy. Female. Humans. Middle Aged. Prognosis. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Blood Transfusion and Donation.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Biol. 1999 Oct;75(10):1293-7 [10549606.001]
  • [Cites] Oncology. 2005;69 Suppl 2:17-21 [16244506.001]
  • [Cites] Br J Haematol. 2001 Apr;113(1):24-31 [11328275.001]
  • [Cites] Int J Radiat Biol. 2001 Dec;77(12):1185-93 [11747543.001]
  • [Cites] Crit Rev Oncol Hematol. 2002 Apr;42(1):65-78 [11923069.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Dec 1;54(5):1345-55 [12459356.001]
  • [Cites] Strahlenther Onkol. 2002 Dec;178(12):727-31 [12491062.001]
  • [Cites] J Trauma. 2003 May;54(5):908-14 [12777903.001]
  • [Cites] Cancer. 2003 Oct 1;98(7):1514-20 [14508840.001]
  • [Cites] Mayo Clin Proc. 2003 Oct;78(10):1274-80 [14531486.001]
  • [Cites] Int J Gynecol Cancer. 2003 Sep-Oct;13(5):633-9 [14675347.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):862-70 [14967443.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 May 1;59(1):67-71 [15093900.001]
  • [Cites] Circulation. 2004 Jun 8;109(22):2755-60 [15148271.001]
  • [Cites] Int J Gynecol Cancer. 2004 Sep-Oct;14(5):903-10 [15361202.001]
  • [Cites] Gynecol Oncol. 2004 Oct;95(1):145-51 [15385124.001]
  • [Cites] Radiology. 1975 Nov;117(2):459-65 [1178882.001]
  • [Cites] Cancer Res. 1989 Sep 1;49(17):4677-81 [2547512.001]
  • [Cites] Int J Cancer. 1993 Dec 2;55(6):996-1002 [8253537.001]
  • [Cites] Surgery. 1994 Mar;115(3):303-9 [8128355.001]
  • [Cites] Am J Surg. 1994 Oct;168(4):340-4 [7943591.001]
  • [Cites] Arch Surg. 1996 Apr;131(4):438-41 [8615733.001]
  • [Cites] Anesthesiology. 1996 Nov;85(5):1219-20 [8916854.001]
  • [Cites] Vox Sang. 1998;74 Suppl 2:315-9 [9704462.001]
  • [Cites] Strahlenther Onkol. 2004 Nov;180(11):671-81 [15549184.001]
  • [Cites] Am J Obstet Gynecol. 2004 Dec;191(6):1907-13 [15592271.001]
  • [Cites] Cancer Radiother. 2005 Mar;9(2):87-95 [15820436.001]
  • [Cites] Cancer Treat Rev. 2005 May;31(3):159-72 [15923088.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Sep 1;63(1):25-36 [16111569.001]
  • [Cites] Hematology. 2005;10 Suppl 1:208-14 [16188675.001]
  • [Cites] Radiother Oncol. 2000 Oct;57(1):13-9 [11033184.001]
  • (PMID = 19108024.001).
  • [ISSN] 0513-5796
  • [Journal-full-title] Yonsei medical journal
  • [ISO-abbreviation] Yonsei Med. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2628023
  •  go-up   go-down


9. Gupta G, Hafiz A, Gandhi JS: Radiation-induced chondrosarcomas: a case report with review of literature. J Cancer Res Ther; 2010 Jul-Sep;6(3):394-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Radiation therapy has become an important component of various cancer treatments.
  • We report a rare case of RIS of left iliac bone in a 62-year-old lady after combined chemotherapy and external beam radiation therapy for cervical carcinoma (stage IIb).
  • [MeSH-minor] Adenocarcinoma / radiotherapy. Female. Humans. Magnetic Resonance Imaging. Middle Aged. Uterine Cervical Neoplasms / radiotherapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21119289.001).
  • [ISSN] 1998-4138
  • [Journal-full-title] Journal of cancer research and therapeutics
  • [ISO-abbreviation] J Cancer Res Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] India
  •  go-up   go-down


10. Corrado G, Santaguida S, Zannoni G, Scambia G, Ferrandina G: Femur metastasis in carcinoma of the uterine cervix: a rare entity. Arch Gynecol Obstet; 2010 May;281(5):963-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Femur metastasis in carcinoma of the uterine cervix: a rare entity.
  • PURPOSE: We report the first case of isolated femur metastasis in a locally advanced cervical cancer (LACC) patients.
  • CASE: A 40-year-old woman presenting with carcinoma of the uterine cervix, FIGO stage IIb was administered concomitant chemo-radiation and achieved clinical partial response.
  • [MeSH-major] Carcinoma / secondary. Femoral Neoplasms / secondary. Femur / pathology. Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Curr Opin Oncol. 2009 Sep;21(5):420-4 [19553814.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2010 Jul 15;77(4):1085-91 [19880262.001]
  • [Cites] Oncologist. 2002;7(4):342-7 [12185296.001]
  • [Cites] J Cancer Res Ther. 2006 Apr-Jun;2(2):79-81 [17998682.001]
  • [Cites] Gynecol Oncol. 1989 Jan;32(1):72-5 [2909450.001]
  • [Cites] Radiographics. 1999 Oct;19 Spec No:S103-16; quiz S264-5 [10517448.001]
  • [Cites] Gynecol Oncol. 2007 Oct;107(1 Suppl 1):S127-32 [17727936.001]
  • [Cites] J Clin Oncol. 2004 Aug 1;22(15):3113-9 [15284262.001]
  • (PMID = 19953258.001).
  • [ISSN] 1432-0711
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC2848922
  •  go-up   go-down


11. Boyd A, Cowie V, Gourley C: The use of cisplatin to treat advanced-stage cervical cancer during pregnancy allows fetal development and prevents cancer progression: report of a case and review of the literature. Int J Gynecol Cancer; 2009 Feb;19(2):273-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The use of cisplatin to treat advanced-stage cervical cancer during pregnancy allows fetal development and prevents cancer progression: report of a case and review of the literature.
  • BACKGROUND: Cervical cancer is one of the most frequently encountered malignancies in pregnancy.
  • For early-stage disease arising in late second/third trimester, treatment may be delayed until delivery.
  • CASE: A 26-year-old woman presented at 21 weeks gestation with a stage IIB high-grade clear cell cervical carcinoma.
  • CONCLUSION: Neoadjuvant cisplatin chemotherapy can be used in stage IIB cervical carcinoma during pregnancy to allow fetal development and prevent disease progression before delivery.
  • [MeSH-major] Adenocarcinoma, Clear Cell / drug therapy. Antineoplastic Agents / therapeutic use. Cisplatin / therapeutic use. Uterine Cervical Neoplasms / drug therapy


12. Moodley M: Round worm infestation as a cause of small bowel anastomotic breakdown following urinary diversion for cervical cancer. Gynecol Oncol; 2007 Dec;107(3):590-1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Round worm infestation as a cause of small bowel anastomotic breakdown following urinary diversion for cervical cancer.
  • BACKGROUND: Vesicovaginal fistulae are well-recognized complications of radiotherapy for the treatment of cervical cancer.
  • CASE: A patient with stage IIB cervical cancer presented with a vesicovaginal fistula 6 years post-radiotherapy.
  • [MeSH-major] Anastomosis, Surgical. Ascariasis / complications. Ileum / parasitology. Postoperative Complications / parasitology. Urinary Diversion. Uterine Cervical Neoplasms / surgery. Vesicovaginal Fistula / surgery


13. Chen YL, He GQ, Wang ED: [Effect of preoperative chemotherapy on bulky cervical cancer by internal iliac arterial infusion]. Zhonghua Fu Chan Ke Za Zhi; 2005 Apr;40(4):231-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effect of preoperative chemotherapy on bulky cervical cancer by internal iliac arterial infusion].
  • OBJECTIVE: To evaluate the effect of preoperative chemotherapy on bulky cervical cancer by internal iliac arterial infusion.
  • METHODS: One hundred and eighty-six patients with bulky cervical cancer were randomly divided into two groups: chemotherapy + radiotherapy group (C + R group, n = 105) and radiotherapy group (R group, n = 81).
  • The effective rate for clinical Ib stage cancer in C + R group was 100.0%, significantly higher than 78.3% in R group (P < 0.01), but for clinical IIa, IIb stage cancers, the effective rate between two groups had no obvious difference (P > 0.05).
  • Postoperative pathologic examinations showed the percentage of cervical tumor residue, parauterine invasion, pelvic lymph node metastasis in C + R group was lower than those of R group (P < 0.01).
  • CONCLUSIONS: Internal iliac arterial infusion chemotherapy can effectively reduce tumor volume, decrease lymph node and subclinical metastasis rates and postoperative recurrence rate; it can also improve radical resectability of patients with stage IIb cervical cancer.
  • [MeSH-major] Preoperative Period. Uterine Cervical Neoplasms / drug therapy


14. Gao JM, Zeng YX, Cui NJ, Lu TX, Zhao C, Xia YF, Ma J, Xie FY: [Staging 915 cases of nasopharyngeal carcinoma after simple radical radiotherapy (Part II)--Checkout of AJCC/UICC staging system (1997)]. Ai Zheng; 2006 Mar;25(3):257-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Staging 915 cases of nasopharyngeal carcinoma after simple radical radiotherapy (Part II)--Checkout of AJCC/UICC staging system (1997)].
  • BACKGROUND & OBJECTIVE: On the basis of our previous research, this study was to validate the rationality of AJCC/UICC staging system (1997) of nasopharyngeal carcinoma (NPC), and to provide some suggestions.
  • METHODS: Survival data of 915 NPC patients, received radical radiotherapy alone in Cancer Center of Sun Yat-sen University from Jan.
  • RESULTS: Cox regression analysis showed that the 5-year survival rate of the 915 patients was significantly correlated to their age and tumor stage classified according to AJCC/UICC (1997) staging system; while that of the 803 patients no more than 60 years old was only significantly correlated to tumor stage.
  • Life table analysis validated that the tumor stage classified according to AJCC/UICC staging system can roughly predict the prognosis, but the differences between stage I and IIa, or IVa and IVb were not significant.
  • Kaplan-Meier analysis showed no significant differences of survival rate between stage T1 and T2a, or T3 and T4 when adjusted by N classification, and between stage N2 and N3a, or N3a and N3b when adjusted by T classification.
  • Therefore, we adjusted stage T2a to T1, stage N1 with inferior cervical nodes metastasis to N2, combined stage N3a and N3b to N3, adjusted stage IIa to I, stage IIb to II, and stage IVb to IVa.
  • CONCLUSION: Taking the impact of age on the prognosis and the interaction between T stage and N stage into consideration, the above modifications should be included when renewing the AJCC/UICC staging system (1997).

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16536975.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


15. Ubieto MA, Paredes P, Martínez S, Ortín J, Fuster D, Torné A, Setoain FJ, Pahisa J, Pons F, Lomeña F: [Ovarian and para-aortic recurrence from cervix cancer detected by PET/CT]. Rev Esp Med Nucl; 2006 Jan-Feb;25(1):31-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Ovarian and para-aortic recurrence from cervix cancer detected by PET/CT].
  • [Transliterated title] Recurrencia ovárica y paraaórtica de un carcinoma de cuello uterino detectada mediante PET/TC.
  • We present the case of a 34-year-old woman diagnosed of an adenosquamous carcinoma of the uterine cervix, stage IIB of the FIGO classification (International Federation of Gynecology and Obstetrics), treated with quimiotherapy, radiotheraphy and brachytheraphy with posterior hysterectomy.
  • PET with FDG (F18-fluorodeoxyglucose) is useful in the staging of primary tumour and in the detection of recurrence in uterine cervical carcinoma, with better sensitivity and specificity than CT and MRI.
  • [MeSH-major] Carcinoma, Adenosquamous / secondary. Lymphatic Metastasis / diagnosis. Ovarian Neoplasms / secondary. Positron-Emission Tomography. Tomography, X-Ray Computed
  • [MeSH-minor] Adult. Antineoplastic Agents, Alkylating / therapeutic use. Brachytherapy. Carcinoma, Squamous Cell / diagnosis. Cisplatin / therapeutic use. Combined Modality Therapy. Female. Humans. Hysterectomy. Radiotherapy, Adjuvant. Uterine Cervical Neoplasms / pathology. Uterine Cervical Neoplasms / therapy

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16540009.001).
  • [ISSN] 0212-6982
  • [Journal-full-title] Revista española de medicina nuclear
  • [ISO-abbreviation] Rev Esp Med Nucl
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


16. Papp Z, Csapó Z, Hupuczi P, Mayer A: Nerve-sparing radical hysterectomy for stage IA2-IIB cervical cancer: 5-year survival of 501 consecutive cases. Eur J Gynaecol Oncol; 2006;27(6):553-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nerve-sparing radical hysterectomy for stage IA2-IIB cervical cancer: 5-year survival of 501 consecutive cases.
  • OBJECTIVE: The purpose of this study was to assess the 5-year survival and morbidity in cases with radical hysterectomy and pelvic lymphadenectomy with pre- and postoperative irradiation performed to treat Stage IA2-IIB cervical cancer.
  • METHODS: During a 10(1/2)-year period between July 1990 and December 2000, 501 consecutive radical hysterectomies with bilateral pelvic lymphadenectomy were performed by the same gynecological surgeon in Stage IA2, IB, IIA and IIB cervical cancer.
  • The absolute 5-year survival rates for the patients in Stage IA2, IB1, IB2, IIA and IIB were 94.4%, 90.7%, 84.1%, 71.1%, and 55.4%, respectively.
  • The respective 5-year survival rates for patients without or with lymph node metastasis were 94.5% and 33.3% in Stage IB2, 81.7% and 48.7% in Stage IIA and 70.2% and 36.5% in Stage IIB, respectively.
  • CONCLUSIONS: Nerve-sparing radical hysterectomy with pelvic lymph node dissection and pre- and postoperative irradiation remains the treatment of choice for most patients with early-stage and even Stage IIB cervical cancer.
  • [MeSH-major] Hypogastric Plexus / injuries. Hysterectomy / methods. Lymph Node Excision / methods. Pelvic Floor / innervation. Uterine Cervical Neoplasms / surgery


17. Haberstich R, Minetti A, Hamid D, Meyer C, Hoffbeck A, Baldauf JJ: [Left colon necrosis after endoscopic para-aortic lymph node exploration in a cervical carcinoma stage IIB]. Ann Chir; 2006 Nov;131(9):553-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Left colon necrosis after endoscopic para-aortic lymph node exploration in a cervical carcinoma stage IIB].
  • [Transliterated title] Nécrose colique gauche après un curage lomboaortique coelioscopique pour cancer du col utérin de stade IIB.
  • Authors report a left colon ischemia six days after laparoscopic para-aortic lymphadenectomy in the staging of advanced cervical carcinoma.
  • [MeSH-major] Colon / pathology. Laparoscopy. Lymph Node Excision / adverse effects. Uterine Cervical Neoplasms / surgery


18. Suprasert P, Srisomboon J, Kasamatsu T: Radical hysterectomy for stage IIB cervical cancer: a review. Int J Gynecol Cancer; 2005 Nov-Dec;15(6):995-1001
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radical hysterectomy for stage IIB cervical cancer: a review.
  • Patients with stage IIB cervical cancer in some countries in Europe and Asia especially in Japan are usually treated with radical hysterectomy and pelvic lymphadenectomy.
  • We present the literature review of radical hysterectomy in stage IIB cervical cancer by searching data since 1980 from Medline, and we found that the parametrial involvement of patients in this stage was only 21-55%, the incidence of pelvic node metastases was about 35-45%, and 5-year survival rate was between 55% and 77%.
  • Lymph node metastases and the number of positive nodes were significant prognostic factors of patients in this stage.
  • [MeSH-major] Hysterectomy. Uterine Cervical Neoplasms / pathology. Uterine Cervical Neoplasms / surgery


19. Wu YY, Liang MR, Li LY, Zeng SY: [Analysis of 4223 hospitalized patients with cervical cancer during 1990-2007]. Zhonghua Fu Chan Ke Za Zhi; 2008 Jun;43(6):433-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analysis of 4223 hospitalized patients with cervical cancer during 1990-2007].
  • OBJECTIVE: To analyze the changes in epidemiology and treatment of hospitalized patients with cervical cancer during 1990-2007.
  • METHODS: Overall, 4648 patients with cervical cancer were diagnosed in our hospital from Jan 1990 to Nov 2007, but only 4223 patients with initial treatment in our hospital were studied retrospectively.
  • Pearson Chi-square test was used to compare the age, stage, histopathologic type and treatment methods between different times. RESULTS:.
  • (1) The mean age of cervical cancer patients gradually decreased over the past 18 years, from 54.4 years during 1990-1999 to 47.2 years during 2000-2007; the proportion of young patients aged < or = 35 years increased from 4.77% (89/1865) during 1990-1999 to 11.75% (277/2358) during 2000-2007. (2) The proportion of patients with cervical cancer (stage I a-II a) increased from 14.
  • 32% (267/1865) during 1990-1999 to 40.75% (961/2358) during 2000-2007, whereas the proportion of patients with cervical cancer (stage II b-IV) decreased from 85.68% (1598/1865) during 1990-1999 to 59.25% (1397/2358) during 2000-2007. (3) There was no significant change in histopathologic type of cervical cancer, and squamous cell carcinoma of cervix remained the main type of cervical cancer. (4) The treatment pattern of cervical cancer changed significantly: radiotherapy was the main method (75.28%) for cervical cancer during 1990-1999, but during 2000-2007, it was replaced by concurrent chemoradiotherapy (35.79%).
  • CONCLUSIONS: The proportion of young women with cervical cancer was increased during 1990-2007, and at the same period early stage cervical cancer increased, but late stage cervical cancer decreased.
  • It is obvious that chemotherapy has become the important therapy in cervical cancer.
  • [MeSH-major] Adenocarcinoma / epidemiology. Adenocarcinoma / pathology. Carcinoma, Squamous Cell. Uterine Cervical Neoplasms
  • [MeSH-minor] Adult. Age Distribution. Aged. Aged, 80 and over. Antineoplastic Protocols. Cervix Uteri / pathology. Combined Modality Therapy. Female. Humans. Incidence. Inpatients. Middle Aged. Neoplasm Staging. Radiotherapy. Retrospective Studies


20. Lataifeh I, Amarin Z, Jaradat I: Stage IIB carcinoma of the cervix that is associated with pelvic kidney: A therapeutic dilemma. Am J Obstet Gynecol; 2007 Dec;197(6):e8-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stage IIB carcinoma of the cervix that is associated with pelvic kidney: A therapeutic dilemma.
  • Locally advanced cervical cancer with congenital pelvic kidney is reported uncommonly.
  • A 50-year-old patient with stage IIB cervical cancer and pelvic kidney was treated with irradiation and concurrent chemotherapy.
  • [MeSH-major] Kidney / abnormalities. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / radiotherapy

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18060936.001).
  • [ISSN] 1097-6868
  • [Journal-full-title] American journal of obstetrics and gynecology
  • [ISO-abbreviation] Am. J. Obstet. Gynecol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


21. Ivanov S: [Wertheim-Meigs radical hysterectomy for cervical cancer stage IIB]. Akush Ginekol (Sofiia); 2007;46(2):22-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Wertheim-Meigs radical hysterectomy for cervical cancer stage IIB].
  • AIM: Our aim was to examine the patients with stage IIB cervical cancer and the use of radical surgical approach-radical hysterectomy Wertheim-Meigs type.
  • MATERIAL AND METHODS: 450 patients were examined for the period of 1995 till 2006, all of them stage IIB cervical cancer.
  • CONCLUSIONS: The use of radical hysterectomy with pelvic lymph node dissection leads to better results in patients with IIB stage cervical cancer.
  • [MeSH-major] Hysterectomy / methods. Uterine Cervical Neoplasms / surgery


22. Nagai T, Okubo T, Sakaguchi R, Seki H, Takeda S: Glassy cell carcinoma of the uterine cervix responsive to neoadjuvant intraarterial chemotherapy. Int J Clin Oncol; 2008 Dec;13(6):541-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glassy cell carcinoma of the uterine cervix responsive to neoadjuvant intraarterial chemotherapy.
  • Described as a poorly differentiated adenosquamous cancer, glassy cell carcinoma of the uterine cervix is a rare disease considered to have an extremely poor prognosis.
  • Saitama Medical Center has been offering neoadjuvant intraarterial chemotherapy (NAC) to cervical cancer patients as a means of avoiding postoperative radiation therapy, achieving downstaging, and improving prognosis.
  • We report a patient with glassy cell carcinoma of the uterine cervix who responded to NAC, and we discuss this case with reference to reports in the literature.
  • A 28-year-old gravida 1, para 0 patient was referred to the Department of Obstetrics and Gynecology at Saitama Medical Center for concurrent cervical cancer at 23.5 gestational weeks.
  • The patient was admitted to our center following the diagnosis of stage IIb cervical cancer (glassy cell carcinoma), to await fetal development, and an elective cesarean section was performed at slightly more than 29 gestational weeks.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Uterine Cervical Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Gynecol Cancer. 2003 May-Jun;13(3):308-12 [12801261.001]
  • [Cites] Gynecol Oncol. 1992 Mar;44(3):254-9 [1541437.001]
  • [Cites] Gynecol Oncol. 1997 Oct;67(1):61-9 [9345358.001]
  • [Cites] Am J Clin Pathol. 1991 Oct;96(4):520-8 [1716415.001]
  • [Cites] Gynecol Oncol. 1979 Oct;8(2):141-51 [499922.001]
  • [Cites] Best Pract Res Clin Obstet Gynaecol. 2005 Aug;19(4):611-30 [15886059.001]
  • [Cites] Cancer Chemother Pharmacol. 2002 Mar;49(3):256-60 [11935219.001]
  • [Cites] Cancer. 1976 May;37(5):2238-46 [1260713.001]
  • [Cites] Lancet. 2000 Apr 1;355(9210):1159-60 [10791384.001]
  • [Cites] Cancer. 1956 Sep-Oct;9(5):971-9 [13364884.001]
  • [Cites] Semin Oncol. 2000 Feb;27(1 Suppl 1):23-7 [10697040.001]
  • [Cites] Aust N Z J Obstet Gynaecol. 1995 Nov;35(4):408-12 [8717566.001]
  • (PMID = 19093183.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 3Z8479ZZ5X / Epirubicin; 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin
  •  go-up   go-down


23. Lee DW, Kim YT, Kim JH, Kim S, Kim SW, Nam EJ, Kim JW: Clinical significance of tumor volume and lymph node involvement assessed by MRI in stage IIB cervical cancer patients treated with concurrent chemoradiation therapy. J Gynecol Oncol; 2010 Mar;21(1):18-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical significance of tumor volume and lymph node involvement assessed by MRI in stage IIB cervical cancer patients treated with concurrent chemoradiation therapy.
  • OBJECTIVE: The purpose of this study was to evaluate the prognostic significance of tumor volume assessed by pretreatment MRI in stage IIB cervical cancer patients with concurrent chemoradiation therapy.
  • METHODS: A retrospective chart review was performed on seventy five patients with cervical cancer who were treated with concurrent weekly cisplatin (40 mg/m(2)) and radiotherapy between January 2000 and April 2007.
  • Potential prognostic factors were age, chemotherapy numbers, histology, tumor diameter and volume, lymph node (LN) involvement and pretreatment squamous cell carcinoma antigen (SCC-Ag) levels.
  • CONCLUSION: Tumor volume and pelvic LN involvement showed possibility to predict overall survival in patient with stage IIB cervical cancer.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Magn Reson Q. 1994 Mar;10(1):22-42 [8161484.001]
  • [Cites] Cancer. 1990 May 1;65(9):1923-7 [2372764.001]
  • [Cites] AJR Am J Roentgenol. 1996 Nov;167(5):1101-8 [8911159.001]
  • [Cites] AJR Am J Roentgenol. 1998 Sep;171(3):707-11 [9725301.001]
  • [Cites] Cancer. 1999 Apr 1;85(7):1547-54 [10193945.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):41-5 [10458216.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Oct 1;45(3):639-44 [10524417.001]
  • [Cites] Zentralbl Gynakol. 2000;122(2):82-91 [10721187.001]
  • [Cites] Int J Gynecol Cancer. 2001 Jul-Aug;11(4):263-71 [11520363.001]
  • [Cites] Gynecol Oncol. 2002 Jan;84(1):115-9 [11748986.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Jan 1;52(1):14-22 [11777618.001]
  • [Cites] Radiol Clin North Am. 2002 May;40(3):577-90, vii [12117194.001]
  • [Cites] Acta Obstet Gynecol Scand. 2002 Dec;81(12):1144-51 [12519111.001]
  • [Cites] Am J Clin Oncol. 2003 Oct;26(5):e163-8 [14528092.001]
  • [Cites] Tumour Biol. 2003 May-Jun;24(3):156-64 [14610320.001]
  • [Cites] J Comput Assist Tomogr. 2004 Sep-Oct;28(5):620-7 [15480035.001]
  • [Cites] Anticancer Res. 2005 May-Jun;25(3A):1663-6 [16033078.001]
  • [Cites] J Clin Oncol. 2005 Oct 20;23(30):7454-9 [16234512.001]
  • [Cites] Int J Gynecol Cancer. 2005 Nov-Dec;15(6):995-1001 [16343175.001]
  • [Cites] Int J Gynecol Cancer. 2006 May-Jun;16(3):1094-100 [16803491.001]
  • [Cites] Cancer. 1992 Apr 1;69(7):1750-8 [1551060.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;23(3):491-9 [1612949.001]
  • [Cites] Cancer. 1992 Aug 1;70(3):648-55 [1623479.001]
  • [Cites] Gynecol Oncol. 1990 Nov;39(2):175-80 [2227592.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Apr 30;29(1):9-16 [8175451.001]
  • (PMID = 20379443.001).
  • [ISSN] 2005-0399
  • [Journal-full-title] Journal of gynecologic oncology
  • [ISO-abbreviation] J Gynecol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2849943
  • [Keywords] NOTNLM ; Cervical neoplasms / Chemoradiation therapy / MRI / Tumor volume
  •  go-up   go-down


24. Mandic A, Novakovic P, Mihajlovic O, Stojiljkovic B, Rajovic J, Davidovic M: Clinical staging and histopathological findings after radical hysterectomy in FIGO stage IIB cervical cancer. J BUON; 2008 Jan-Mar;13(1):51-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical staging and histopathological findings after radical hysterectomy in FIGO stage IIB cervical cancer.
  • PURPOSE: Advanced cervical cancer still represents a major health care challenge in the developing world.
  • According to standard protocols the treatment of choice for stage IIB cervical cancer is cisplatin-based chemoradiotherapy.
  • However, in some European countries, and especially in Japan, patients with stage IIB cervical cancer are generally treated with radical hysterectomy as initial treatment.
  • The aim of this study was to compare clinical stage with pathological findings, and also to correlate any relationship between parametrial infiltration and nodal status.
  • PATIENTS AND METHODS: From 1997 to 2006, 26 patients with FIGO stage IIB cervical cancer were radically operated (Piver class III operation).
  • The histopathological types of cervical tumors were: squamous cell carcinoma 80%, adenosquamous carcinoma 15% and adenocarcinoma 5%.
  • [MeSH-major] Hysterectomy. Uterine Cervical Neoplasms / pathology


25. Chen CH, Chao KC, Wang PH: Advanced cervical squamous cell carcinoma with skin metastasis. Taiwan J Obstet Gynecol; 2007 Sep;46(3):264-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advanced cervical squamous cell carcinoma with skin metastasis.
  • OBJECTIVE: Although cervical cancer is a very common gynecologic malignancy, skin metastasis presenting as an initial sign of recurrent or persistent disease is extremely rare.
  • CASE REPORT: A 72-year-old woman was diagnosed with squamous cell carcinoma of the cervix (FIGO stage, IIB), which was treated with concurrent chemoradiation.
  • Excision biopsy was performed and showed metastatic carcinoma, favoring a squamous cell type.
  • CONCLUSION: This report supports the concept that skin metastasis is a late manifestation and an ominous sign for cervical cancer patients, and also indicates the uncontrolled or widespread metastasis of the disease.
  • [MeSH-major] Carcinoma, Squamous Cell / secondary. Skin Neoplasms / secondary. Uterine Cervical Neoplasms / pathology


26. Noh JM, Huh SJ: Two cases of post-radiation osteosarcoma of the sacrum after pelvic irradiation for uterine cervical cancer. Eur J Gynaecol Oncol; 2007;28(6):497-500
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Two cases of post-radiation osteosarcoma of the sacrum after pelvic irradiation for uterine cervical cancer.
  • BACKGROUND: Post-radiation pelvic bone sarcoma can result as a long-term sequela of pelvic irradiation for uterine cervical cancer.
  • CASE: A 59-year-old woman who had received pelvic irradiation for Stage IIB uterine cervical cancer 16 years before was diagnosed as having post-radiation osteosarcoma of the sacrum.
  • Another 66-year-old woman who had received pelvic irradiation for Stage IIIB uterine cervical cancer seven years previously was also diagnosed as having pleomorphic sarcoma of the sacrum.
  • [MeSH-major] Bone Neoplasms / secondary. Neoplasms, Radiation-Induced / etiology. Osteosarcoma / secondary. Sacrum / pathology. Uterine Cervical Neoplasms / radiotherapy


27. Yamashita H, Okuma K, Kawana K, Nakagawa S, Oda K, Yano T, Kobayashi S, Wakui R, Ohtomo K, Nakagawa K: Comparison between conventional surgery plus postoperative adjuvant radiotherapy and concurrent chemoradiation for FIGO stage IIB cervical carcinoma: a retrospective study. Am J Clin Oncol; 2010 Dec;33(6):583-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison between conventional surgery plus postoperative adjuvant radiotherapy and concurrent chemoradiation for FIGO stage IIB cervical carcinoma: a retrospective study.
  • OBJECTIVE: To compare treatment outcome of conventional surgery followed by adjuvant postoperative radiotherapy (PORT) versus concurrent chemoradiation therapy (cCRT) for stage IIB cervical carcinoma.
  • METHODS: A retrospective analysis was conducted of 59 patients with stage IIB uterine cervical cancer treated with radical surgery plus PORT (N = 34) or cCRT-alone (N = 25) from April 1996 to June 2008.
  • CONCLUSION: This retrospective study suggests that survival results with cCRT and with conventional surgery plus PORT for patients with stage IIB cervical carcinoma are comparable.
  • [MeSH-major] Hysterectomy / methods. Uterine Cervical Neoplasms / pathology. Uterine Cervical Neoplasms / therapy


28. Saitoh J, Sakurai H, Suzuki Y, Katoh H, Takahashi T, Nakano T: Metastatic angiosarcoma of the lung with alveolar hemorrhage. Jpn J Radiol; 2009 Nov;27(9):381-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 76-year-old woman was diagnosed as stage IIb uterine cervical cancer.
  • The cancer disappeared after radiotherapy.
  • No recurrence of the uterine cervical cancer was detected.
  • [MeSH-major] Hemangiosarcoma / complications. Hemangiosarcoma / secondary. Hemorrhage / etiology. Lung Neoplasms / complications. Lung Neoplasms / secondary. Uterine Cervical Neoplasms / pathology


29. Kennedy CM, Peterson LB, Galask RP: Erosive vulvar lichen planus: a cohort at risk for cancer? J Reprod Med; 2008 Oct;53(10):781-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Erosive vulvar lichen planus: a cohort at risk for cancer?
  • OBJECTIVE: To determine the occurrence of cancer, including vulvovaginal squamous cell carcinoma (SCC), among women after diagnosis of erosive vulvar lichen planus (LP).
  • RESULTS: A diagnosis of cancer was made in 5 women after diagnosis of erosive vulvar LP.
  • Of these, 1 had stage II vulvar SCC after treatment for stage IIB cervical cancer, and 2 with oral LP had subsequent diagnoses of oral or esophageal SCC.
  • The remaining 2 cancer diagnoses included cervical adenocarcinoma in situ and rectal adenocarcinoma.
  • [MeSH-major] Carcinoma, Squamous Cell / epidemiology. Lichen Planus / epidemiology. Vulvar Diseases / epidemiology. Vulvar Neoplasms / epidemiology


30. Shi HR, Wu QH, Suo ZH, Nesland JM: [Correlation between methylation of 5'-CpG islands and inactivation of FHIT gene in cervical cancer]. Ai Zheng; 2005 Jan;24(1):7-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Correlation between methylation of 5'-CpG islands and inactivation of FHIT gene in cervical cancer].
  • This study was designed to explore relationship of methylation of 5'-CpG islands with inactivation of FHIT gene in cervical cancer.
  • METHODS: Methylation of 5'-CpG islands in 10 normal cervical squamous epithelial tissues, and 40 cervical cancer tissues was detected with methylation specific polymerase chain reaction (MSP), protein expression of FHIT was detected with immunohistochemistry, and their correlations with clinicopathologic features of cervical cancer were statistically analyzed. RESULTS:.
  • (1) The 5'-CpG islands methylation rate of FHIT gene in cervical cancer tissues was 40.0% (16/40), while no methylation of FHIT gene was found in normal cervical tissues. (2) The methylation rates of FHIT gene in cervical cancer of stage I was 14.3% (2/14), significantly lower than that in cervical cancer of stage II (56.5%, 13/23) (P<0.05). (3) Expression of FHIT protein in cervical cancer was 33.0% (12/40), significantly lower than that in normal cervical tissue (100%, 10/10) (P<0.05).
  • CONCLUSION: The 5'-CpG islands methylation may play an important role in inactivation of FHIT gene, and may be related with tumorigenesis of cervical cancer.
  • [MeSH-major] Acid Anhydride Hydrolases / biosynthesis. CpG Islands / genetics. DNA Methylation. Gene Silencing. Neoplasm Proteins / biosynthesis. Uterine Cervical Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Female. Genes, Tumor Suppressor. Humans. Middle Aged. Neoplasm Staging






Advertisement